Long-acting treatments bring new hope to hemophilia patients

03/10/2014 | Reuters

Long-acting drugs for hemophilia have emerged that could reduce the need for regular intravenous infusions of blood clotting agents. Treatments such as Biogen's Alprolix and Novo Nordisk's investigational drug N9-GP could help cut the cost of existing treatments, according to industry experts. Biotech companies such as BioMarin Pharmaceutical and Sangamo BioSciences are working on gene therapies that could enable people with hemophilia to make their own clotting factor.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY